Core Viewpoint - The company BGI Genomics announced a preliminary transfer price of 44.1 yuan per share for its non-public share transfer, which is based on the inquiry subscription situation as of September 15, 2025 [1] Summary by Relevant Categories Share Transfer Details - The share transfer is a non-public transfer and will not be conducted through centralized bidding or block trading methods [1] - The shares acquired through this inquiry transfer cannot be transferred by the acquirer within six months after the acquisition [1] Investor Profile - The acquirer of the shares will be institutional investors who possess the necessary pricing capability and risk tolerance [1]

证券代码：300676 证券简称：华大基因 公告编号：2025-051 深圳华大基因股份有限公司 股东询价转让定价情况提示性公告 股东深圳华大基因科技有限公司保证向深圳华大基因股份有限公司提供的信息内容不存在 任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 根据2025年9月15日询价申购情况，深圳华大基因股份有限公司（以下简称公司） 股东深圳华大基因科技有限公司询价转让（以下简称本次询价转让）初步确定的转 让价格为44.10元/股； 本次询价转让为非公开转让，不通过集中竞价交易方式或大宗交易方式进行，不属 于通过二级市场减持。受让方通过询价转让受让的股份，在受让后6个月内不得转 让； 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资者。 深圳华大基因股份有限公司董事会 2025 年 9 月 15 日 （一）本次询价转让尚存在拟转让股份被司法冻结、扣划等风险。询价转让的最终 结果以中国证券登记结算有限责任公司深圳分公司最终办理结果为准。 （二）本次询价转让不会导致公司控制权发 ...

Group 1 - On September 15, BGI Genomics executed a block trade of 522,100 shares, with a transaction value of 25 million yuan, accounting for 2.98% of the total trading volume for that day [1][2] - The transaction price was 47.88 yuan, representing a 10% discount compared to the market closing price of 53.2 yuan [1][2]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 深圳华大基因股份有限公司（以下简称公司或上市公司）近日收到公司持股5% 以上股东深圳生华投资企业（有限合伙）（以下简称生华投资）的通知，获悉生华 投资将其持有的部分公司股份办理了解除质押及再质押，相应的解除质押及再质押 登记手续已通过中国证券登记结算有限责任公司深圳分公司办理完毕。现将具体内 容公告如下： 一、股东股份解除质押及再质押的基本情况 | 股东名称 | 是否为控股 股东或第一 | 本次解除质 | 占其所持股 | 占公司 | 质押起始 | 质押解除日 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 押股份数量 | | 总股本 | | | 质权人 | | | 大股东及其 | | 份比例 | | 日期 | 期 | | | | 一致行动人 | （股） | | 比例 | | | | | 深圳生华投资 | | | | | | | 中国银行股份 | | 企业（有限合 | 否 | 4,850,000 | 15.23% | 1.16% | 2024/ ...

丨 2025年9月15日 星期一 丨 NO.1 百洋医药拟以24%股权战略投资济坤医药 百洋医药公告，公司与天津济坤医药签订战略合作协议，百洋医药战略投资济坤医药，拟持有其24%股 权，进而锁定济坤医药旗下用于治疗肺纤维化的1类创新药的所有权益。同时，公司对济坤医药持有的 所有产品的全球化合物权益享有同等条件下优先购买权。 每经记者｜甄素静 每经编辑｜张海妮 点评：华大基因控股股东华大控股拟转让4%股份，借询价转让获得资金，用于细胞组学、时空组学等 前沿科技孵化。此次布局或为华大基因开拓新增长曲线。 NO.4 索元生物在研新药关键性研究发表于《JAMA精神病学》 索元生物宣布，其关键性ENLIGHTEN试验成果以专题形式发表于精神病学顶级期刊《JAMA精神病 学》。研究结果显示，在携带新型药物基因组生物标志物ANK3的难治性抑郁症（TRD）患者中， DB104（Liafensine）展现出显著疗效。 点评：百洋医药战略投资济坤医药，锁定肺纤维化创新药JK1033项目权益，有望丰富创新药管线。叠 加其在肝纤维化领域的产品，可构建纤维化疾病治疗产品组合优势。 NO.2 千金药业：发行股份购买资产获同意批复 千金药 ...

Group 1 - The core point of the news is that BGI Genomics (华大基因) is undergoing a share transfer plan initiated by its controlling shareholder, BGI Group, to raise funds for cutting-edge technology incubation [1][2] - BGI Group plans to transfer 16.73 million shares, representing 4% of the total share capital, to institutional investors with appropriate pricing and risk-bearing capabilities [1][2] - The funds raised from the share transfer will be prioritized for supporting the incubation of new productivity directions in advanced technology [2] Group 2 - BGI Genomics is positioned as the strongest platform for industrialization and commercialization within BGI Group, focusing on core advantages in reproductive health, cancer prevention, chronic disease management, and infectious disease diagnosis [3] - The company is currently in a critical business transformation period, launching new products aimed at enhancing public health and personalized health management [3] - Future growth drivers for BGI Genomics include increasing health demands due to demographic changes, urgent needs for major disease prevention, and ongoing support from policies and payment systems [3]

Core Viewpoint - The controlling shareholder of BGI Genomics plans to transfer 16.73 million shares, representing 4% of the total share capital, to support cutting-edge technology incubation, indicating a strategic focus on long-term growth and innovation [1][2]. Group 1: Share Transfer Details - The share transfer will be conducted through a non-public inquiry transfer, not affecting the secondary market through traditional reduction methods [1]. - The transferee must be an institutional investor with appropriate pricing capabilities and risk tolerance, and the shares cannot be transferred within six months post-acquisition [1]. Group 2: Strategic Implications - The funds raised from the share transfer will be prioritized for supporting the incubation of new productivity technologies, aligning with BGI's long-term vision [2]. - BGI Genomics aims to leverage its position as a commercialization platform for BGI Group's technological advancements, potentially translating innovations into predictable revenue growth [2]. Group 3: Business Transition and Focus - BGI Genomics is currently undergoing a critical business transition, addressing common industry pain points such as complexity, high costs, and barriers to interpretation and consultation [2]. - The company is increasing its investment in research and development to enhance automation and intelligence capabilities, aiming to expand its business boundaries and improve service value [2].

华大基因（300676）(300676.SZ)发布股东询价转让计划书，本次拟参与询价转让的股东为深圳华大基 因科技有限公司(以下称华大控股或出让方)，出让方拟转让股份总数为1673.27万股，占公司总股本的比 例为4.00%。 ...

Group 1 - The core point of the article is that BGI Genomics (300676.SZ) has announced a share transfer plan involving a total of 16.7327 million shares, which represents 4.00% of the company's total share capital [1]

中国国际金融股份有限公司 关于深圳华大基因股份有限公司 股东向特定机构投资者询价转让股份 相关资格的核查意见 中国国际金融股份有限公司（以下简称"中金公司"）受深圳华大基因股份有限 公司（以下简称"华大基因"）股东深圳华大基因科技有限公司（以下称"出让方"） 委托，组织实施本次华大基因股东向特定机构投资者询价转让（以下简称"本次询价 转让"）。 根据《上市公司股东减持股份管理暂行办法》《深圳证券交易所创业板股票上市 规则（2025 年修订）》《深圳证券交易所上市公司自律监管指引第 18 号——股东及 董事、高级管理人员减持股份（2025 年修订）》（以下简称"《减持指引》"）《深 圳证券交易所上市公司自律监管指引第 16 号——创业板上市公司股东询价和配售方式 转让股份（2025 年修订）》（以下简称"《指引第 16 号》"）等相关规定，中金公 司对参与本次询价出让方的相关资格进行了核查。 本次询价转让的委托情况、出让方相关资格的核查情况及核查意见如下： 一、本次询价转让的委托 中金公司已收到出让方关于本次询价转让的委托，委托中金公司组织实施本次询 价转让。 1 二、关于参与本次询价转让股东相关资格的核查情况 ...